These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 31120519)

  • 41. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
    Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
    Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease.
    Cotter TG; Rinella M
    Gastroenterology; 2020 May; 158(7):1851-1864. PubMed ID: 32061595
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Real-life Perception and Practice Patterns of NAFLD/NASH in Romania: Results of a Survey Completed by 102 Board-certified Gastroenterologists.
    Iacob S; Ester C; Lita M; Ratziu V; Gheorghe L
    J Gastrointestin Liver Dis; 2016 Jun; 25(2):183-9. PubMed ID: 27308649
    [TBL] [Abstract][Full Text] [Related]  

  • 44. "We could have used a lot more of this before…": A qualitative study understanding barriers and facilitators to implementing a provincial PPE safety coach program during the COVID-19 pandemic.
    Gagnon H; Hearn K; Tsang C; Yip E; Stuber L; Ile E; Bridger L; Saulnier G; Hanson HM; Leal J
    Am J Infect Control; 2024 Aug; 52(8):947-957. PubMed ID: 38492807
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Health professional and patient views of a novel prognostic test for melanoma: A theoretically informed qualitative study.
    Lecouturier J; Bosomworth H; Labus M; Ellis RA; Lovat PE
    PLoS One; 2022; 17(4):e0265048. PubMed ID: 35377887
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Barriers and enablers to the implementation of evidence-based practice in pressure ulcer prevention and management in an integrated community care setting: A qualitative study informed by the theoretical domains framework.
    Taylor C; Mulligan K; McGraw C
    Health Soc Care Community; 2021 May; 29(3):766-779. PubMed ID: 33662173
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cross-sectional pilot study to assess primary healthcare workers' knowledge of nonalcoholic fatty liver disease in a marginalized community in Mexico.
    Vidal-Cevallos P; Ordóñez-Vázquez AL; Procopio-Mosso O; Cardoso-Arias R; Uribe M; Chávez-Tapia NC
    Sci Rep; 2021 Jun; 11(1):12100. PubMed ID: 34103552
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Applying the Theoretical Domains Framework to identify barriers and targeted interventions to enhance nurses' use of electronic medication management systems in two Australian hospitals.
    Debono D; Taylor N; Lipworth W; Greenfield D; Travaglia J; Black D; Braithwaite J
    Implement Sci; 2017 Mar; 12(1):42. PubMed ID: 28347319
    [TBL] [Abstract][Full Text] [Related]  

  • 49. TASL Practice Guidance on the Clinical Assessment and Management of Patients with Nonalcoholic Fatty Liver Disease.
    Yilmaz Y; Zeybel M; Adali G; Cosar AM; Sertesen E; Gokcan H; Bahcecioglu HI; Sahin M; Tulunay C; Ergun I; Turan I; Idilman IS; Celikel C; Kirimlioglu H; Akyol G; Yilmaz F; Sokmensuer C; Guveli H; Akarca US; Akyuz U; Genc V; Akyildiz M; Yazihan N; Tutar E; Ates F; Dincer D; Balaban Y; Kiyici M; Akdogan M; Sonsuz A; Idilman R; ; Yapali S; Dursun H; Aladag M; Satman I; Karcaaltincaba M; Arikan C; Gulerman F; Selimoglu A; Ozen H; Basaranoglu M; Karakan T; Yurci A; Demir K; Koruk M; Uygun A; Sezgin O; Gulec S; Besisik F; Simsek H; Hulagu S; Tozun N; Mardinoglu A; Demir M; Doganay L; Akarsu M; Karasu Z; Kaymakoglu S; Gunsar F
    Hepatol Forum; 2023; 4(Suppl 1):1-32. PubMed ID: 37920782
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes.
    Ahmed A; Wong RJ; Harrison SA
    Clin Gastroenterol Hepatol; 2015 Nov; 13(12):2062-70. PubMed ID: 26226097
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management.
    Chrysavgis L; Ztriva E; Protopapas A; Tziomalos K; Cholongitas E
    World J Gastroenterol; 2020 Nov; 26(42):6514-6528. PubMed ID: 33268944
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Using the Theoretical Domains Framework (TDF) to understand adherence to multiple evidence-based indicators in primary care: a qualitative study.
    Lawton R; Heyhoe J; Louch G; Ingleson E; Glidewell L; Willis TA; McEachan RR; Foy R;
    Implement Sci; 2016 Aug; 11():113. PubMed ID: 27502590
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients.
    Cheung A; Figueredo C; Rinella ME
    Am J Gastroenterol; 2019 Apr; 114(4):579-590. PubMed ID: 30839326
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improving appropriate polypharmacy for older people in primary care: selecting components of an evidence-based intervention to target prescribing and dispensing.
    Cadogan CA; Ryan C; Francis JJ; Gormley GJ; Passmore P; Kerse N; Hughes CM
    Implement Sci; 2015 Nov; 10():161. PubMed ID: 26573745
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
    Ota T
    Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preparing for the NASH Epidemic: A Call to Action.
    Kanwal F; Shubrook JH; Younossi Z; Natarajan Y; Bugianesi E; Rinella ME; Harrison SA; Mantzoros C; Pfotenhauer K; Klein S; Eckel RH; Kruger D; El-Serag H; Cusi K
    Gastroenterology; 2021 Sep; 161(3):1030-1042.e8. PubMed ID: 34416976
    [TBL] [Abstract][Full Text] [Related]  

  • 57. General practitioner views on the determinants of test ordering: a theory-based qualitative approach to the development of an intervention to improve immunoglobulin requests in primary care.
    Cadogan SL; McHugh SM; Bradley CP; Browne JP; Cahill MR
    Implement Sci; 2016 Jul; 11(1):102. PubMed ID: 27435839
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-alcoholic Fatty Liver Disease and Diabetes Mellitus.
    Khneizer G; Rizvi S; Gawrieh S
    Adv Exp Med Biol; 2021; 1307():417-440. PubMed ID: 32424494
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Liver Disease: Nonalcoholic Fatty Liver Disease.
    Cooper J; Baumgartner K; Smith A; St Louis J
    FP Essent; 2021 Dec; 511():29-35. PubMed ID: 34855339
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Advances in diagnosis and treatment of nonalcoholic fatty liver disease].
    Zhu C; Zhou D; Fan J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):81-4. PubMed ID: 26983471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.